Science · 1998 · 460 citations · 16 references
Life SciencesCardiologyPharmacologyCell SignalingPathophysiologySignal TransductionCalcineurin Inhibitor TherapyCalcineurin InhibitorsCalcium SignalingCardiovascular DiseaseCardiovascular Molecular PhysiologyInherited CardiomyopathiesCalcineurin Pathway InhibitionHypertrophic Cardiomyopathy Drug TherapyPhosphatase InhibitionProtein Phosphatase 2B (Calcineurin)Tropomyosin Regulation
Hypertrophic cardiomyopathy is an inherited heart disease affecting about 1 in 500 individuals. Inhibiting calcineurin with cyclosporin or FK506 prevented hypertrophy in genetically predisposed mice and reduced pressure‑overload hypertrophy in rats, indicating therapeutic promise.
Hypertrophic cardiomyopathy (HCM) is an inherited form of heart disease that affects 1 in 500 individuals. Here it is shown that calcineurin, a calcium-regulated phosphatase, plays a critical role in the pathogenesis of HCM. Administration of the calcineurin inhibitors cyclosporin and FK506 prevented disease in mice that were genetically predisposed to develop HCM as a result of aberrant expression of tropomodulin, myosin light chain–2, or fetal β-tropomyosin in the heart. Cyclosporin had a similar effect in a rat model of pressure-overload hypertrophy. These results suggest that calcineurin inhibitors merit investigation as potential therapeutics for certain forms of human heart disease.
16
A Calcineurin-Dependent Transcriptional Pathway for Cardiac Hypertrophy
Jeffery D. Molkentin, Jianrong Lu, Christopher L. Antos et al. · Cell · 1998 · 2.6K citations · Full text
Prevalence of Hypertrophic Cardiomyopathy in a General Population of Young Adults
Barry J. Maron, Julius M. Gardin, John M. Flack et al. · Circulation · 1995 · 2.3K citations · Full text